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Missense Mutations in the N-Terminal Domain of Human Phenylalanine
Hydroxylase Interfere with Binding of Regulatory Phenylalanine
Torben Gjetting, Marie Petersen, Per Guldberg, and Flemming Gu¨ttler
The John F. Kennedy Institute, Glostrup, Denmark
Hyperphenylalaninemia due to a deficiency of phenylalanine hydroxylase (PAH) is an autosomal recessive disorder
caused by 1400 mutations in the PAH gene. Recent work has suggested that the majority of PAHmissense mutations
impair enzyme activity by causing increased protein instability and aggregation. In this study, we describe an
alternative mechanism by which some PAH mutations may render PAH defective. Database searches were used to
identify regions in the N-terminal domain of PAH with homology to the regulatory domain of prephenate dehy-
dratase (PDH), the rate-limiting enzyme in the bacterial phenylalanine biosynthesis pathway. Naturally occurring
N-terminal PAH mutations are distributed in a nonrandom pattern and cluster within residues 46–48 (GAL) and
65–69 (IESRP), two motifs highly conserved in PDH. To examine whether N-terminal PAH mutations affect the
ability of PAH to bind phenylalanine at the regulatory domain, wild-type and five mutant (G46S, A47V, T63P/
H64N, I65T, and R68S) forms of the N-terminal domain (residues 2–120) of human PAH were expressed as fusion
proteins in Escherichia coli. Binding studies showed that the wild-type form of this domain specifically binds
phenylalanine, whereas all mutations abolished or significantly reduced this phenylalanine-binding capacity. Our
data suggest that impairment of phenylalanine-mediated activation of PAH may be an important disease-causing
mechanism of some N-terminal PAH mutations, which may explain some well-documented genotype-phenotype
discrepancies in PAH deficiency.
Introduction
Phenylalanine hydroxylase (PAH; phenylalanine 4-
mono-oxygenase, EC 1.14.16.1) is responsible for the
enzymatic conversion of L-phenylalanine to L-tyrosine
in humans. Defects in PAH enzymatic activity caused by
mutations in the PAH gene are associated with hyper-
phenylalaninemia and phenylketonuria (PKU [MIM
261600]). The disorder is transmitted in an autosomal
recessive pattern and is the most common inborn error
of amino acid metabolism among whites, with an av-
erage incidence of 1 in 10,000 (Scriver and Kaufman
2001).More than 400 PAH mutations and amuch larger
number of PAH-mutation genotypes have been identified
in patients with hyperphenylalaninemia (Scriver et al.
2000), which may explain the broad continuum of met-
abolic and biochemical phenotypes associated with PAH
deficiency (Okano et al. 1991; Kayaalp et al. 1997; Guld-
berg et al. 1998). Of the known PAH mutations, ∼60%
are missense variants, of which the molecular conse-
quences are not directly evident.
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Monomeric PAH is organized into three functional
domains, including an N-terminal regulatory domain
(residues 2–120), a catalytic domain (residues 121–
427), and an oligomerization domain at the extreme C-
terminal end (residues 428–452) (Hufton et al. 1995;
Erlandsen et al. 1997; Fusetti et al. 1998; Kobe et al.
1999). At physiological conditions, PAH is found in an
equilibrium between dimeric, tetrameric, and—to some
extent—higher oligomeric forms (Martinez et al. 1995).
Stability studies have demonstrated that even low con-
centrations of chemical denaturants cause dramatic
shifts in the oligomeric composition (Kleppe et al.
1999). This relatively low stability of native PAH may
explain recent findings that many naturally occurring
mutant variants show a high degree of instability and
susceptibility towards aggregation and degradation (Ei-
ken et al. 1996; Bjørgo et al. 1998; Waters et al. 1998a,
1998b, 1999, 2000; Gjetting et al. 2001). The notion
that misfolding and structural instability are important
mechanisms of enzyme dysfunction is also supported by
the mapping of disease-causing missensemutations onto
the proposed model of tetrameric PAH. With very few
exceptions, mutations affect residues that are located
outside the active site and appear important for the
overall integrity of the enzyme (Fusetti et al. 1998; Er-
landsen and Stevens 1999; Jennings et al. 2000).
Recent crystallographic analysis of rat PAH has pro-
vided important insights into the functional basis for
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regulation of this enzyme (Kobe et al. 1999). Notably,
the N-terminal regulatory domain exhibits a double bab
motif that is common to a number of proteins, including
several involved in amino acid metabolism. This obser-
vation is compatible with previous biochemical evidence
(Shiman 1980; Kaufman 1993) that PAH binds phe-
nylalanine at two physically distinct sites: an allosteric
regulatory or activating site and a catalytic site. Ac-
cording to the proposed model (Kobe et al. 1999), the
regulatory domain and the catalytic domain of PAH are
connected by a flexible hinge joint. The extreme N-
terminal end (residues 1–33) constitutes an autoregu-
latory sequence that extends from the core of the reg-
ulatory domain into the active site and serves to restrict
access of phenylalanine to the active site. Removal of
this sequence gives rise to an enzyme that does not re-
quire activation by phenylalanine and is not inhibited
by (6R)-5,6,7,8-tetrahydrobiopterin (BH4), the natural
cofactor of PAH (Jennings et al. 2001; Wang et al.
2001). These findings suggest that binding of phenyl-
alanine to the regulatory domain of PAH induces con-
formational changes that displace the autoregulatory
sequence from its position at the active site. Activation
of PAH is a cooperative, reversible process involving all
three functional domains and all four subunits in the
holoenzyme (Shiman et al. 1990; Kaufman 1993; Davis
et al. 1997).
Although there is now substantial evidence that many
missense mutations in the catalytic domain of PAH
cause enhanced aggregation and rapid degradation in
vitro, presumably due to protein misfolding (Knapps-
kog et al. 1996; Bjørgo et al. 1998; Waters et al. 1998a),
the effects of missense mutations in the N-terminal reg-
ulatory domain are less clear. Size-exclusion chroma-
tography and pulse-chase experiments have clearly dem-
onstrated that some mutations in the N-terminal
domain reduce PAH protein levels in cultured cells and
that the increased protein turnover can be inhibited by
the addition of protease inhibitors (Eiken et al. 1996;
Waters et al. 1998a, 1999, 2000). Nevertheless, the rate
of protein turnover appeared to be significantly lower
for N-terminal mutations than for C-terminalmutations
(Waters et al. 1998a). Furthermore, recent stability stud-
ies of mutant proteins expressed in Escherichia coli
showed that, in general, mutations in the regulatory
domain were associated with relatively stable proteins
compared to most mutations in the catalytic domain
(Gjetting et al. 2001). Collectively, these data suggest
that a distinct mechanism may operate, alone or in con-
cert, to cause loss of PAH function, leading to hyper-
phenylalaninemia. Here, we show that many naturally
occurring N-terminal PAH mutations map to residues
highly conserved in prephenate dehydratase (PDH), a
key enzyme in bacterial phenylalanine biosynthesis, and
that these mutations reduce or abolish the ability of the
N-terminal domain of PAH to bind phenylalanine.
Materials and Methods
Recombinant DNA Techniques
Construction of mutant human PAH cDNAs inserted
into pET-11a has been described in detail elsewhere
(Gjetting et al. 2001). To generate wild-type and mutant
forms of the N-terminal region of PAH (residues 2–
120), the mutant PAH cDNAs in pET-11a were used as
templates for PCR amplification, using pfu DNA poly-
merase (Stratagene) and the primers PAH-N-XmnI-for
(5′-GAG GGA AGG ATT TCC ACT GCG GTC CTG
GAA AAC CC-3′) and PAH-N-BamHI-rev (5′-CGG
GAT CCT TAG AAC CAG GGC ACT GTG TCT TT-
3′). The PCR products were digested with XmnI and
BamHI and were ligated into the vector, pMAL-c2 (New
England Biolabs), also prepared with these enzymes.
Control sequencing of all DNA extended in vitro was
performed with a 32P-labeled primer, using the Thermo
Sequenase cycle sequencing kit (Amersham Pharmacia
Biotech).
Expression and Purification
The N-terminal domain of PAH fused to maltose-
binding protein (MBP) was expressed in freshly trans-
formed E. coli (Strain TB-1). Overnight cultures were
diluted 20 times in fresh medium and grown for 2 h at
30C before expression was induced by addition of IPTG
(0.5 mM). The cells were harvested by centrifugation
after 2 h of incubation at 30C. Subsequent protein ex-
traction and affinity chromatography were carried out
essentially as recommended by the supplier (New Eng-
land Biolabs). Eluted protein was concentrated by ul-
trafiltration with a cut-off of 10 kDa (Millipore), and
the protein concentration was measured spectrophoto-
metrically using a theoretical extinction coefficient of
73,000 ABS280 nm cm
—1M1, calculated with the program
PEPTIDESTRUCTURE (Genetics Computer Group).
Protein Gel Analysis
The protocol used for SDS-PAGE was adopted from
previously described procedures (Harlow and Lane
1988). For nondenaturing PAGE, purified protein was
loaded onto precast gels containing a 4%–15% poly-
acrylamide gradient (Bio-Rad) and was subjected to elec-
trophoresis at 100 V for 2 h in a Tris-glycine running
buffer without SDS, as described elsewhere (Gjetting et
al. 2001). The separated proteins were stained with
GelCode (Pierce Chemical). For quantitative analyses,
the gels were examined by use of the 1D Gel Analysis
PHORETIX Software (Phoretix).
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Phenylalanine Binding Assays
Purified fusion protein (50 mM) and substrate (25–
400 mM unlabeled phenylalanine, 0.1 mCi 14C-labeled
phenylalanine [NEN Life Science Products] were mixed
in a total volume of 50 ml, were incubated at 20C for
1 h, and then were transferred to an ultrafiltration filter
with a 10 kDa cutoff (Microcon). After an additional
incubation at 20C for 1 h, the samples were centrifuged
for 5 min at 10,000# g, resulting in ∼25 ml centrifugate
containing unbound phenylalanine and 25 ml retentate
containing unbound and bound phenylalanine. Ten-mi-
croliter aliquots of these samples were counted by scin-
tillation, using Ultima Gold scintillation liquid (Packard
BioScience). The concentration of bound phenylalanine
was calculated according to the formula (cpm r
, where cpmr is radioactivitycpm )/(cpm  cpm )# Cc r c phe
in the retentate, cpmc is radioactivity in the centrifugate,
and Cphe is the initial phenylalanine concentration.Under
the assumption of one phenylalanine-binding site per
monomer, the percentage of occupied binding sites was
calculated as (concentration of bound phenylalanine/
protein concentration) # 100%. Thus, the occupancy
of binding sites was used as a measure for binding.
Results
Homology between the Regulatory Domains of PAH
and PDH
Protein database searches were used to identify pro-
teins with sequence homology to human PAH. Overall,
weak homology was found between the N-terminal reg-
ulatory domain of PAH and the regulatory domain of
PDH in a wide range of microorganisms. Nevertheless,
very strong homology was found for two motifs, GAL
(residues 46–48 in human PAH) and (I/L)ESRP (residues
65–69 in human PAH) (fig. 1). The residues in these
regions were conserved in PAH from all examined eu-
karyotic species and in PDH from all prokaryotic spe-
cies, with the exception of Corynebacterium glutamicum
(GSL instead of GAL) and Amycolatopsis methanolica
(GTL instead of GAL and LADRP instead of LESRP).
In addition to these nearly invariant motifs, several ad-
ditional residues showed very high degrees of evolu-
tionary conservation, including those corresponding to
I38, L52, F55, V60, N61, L62, T63, Y77, F79, I95, and
I102 in human PAH. The overall structure of the region
comprising the GAL and (I/L)ESRP motifs were con-
served in human tyrosine hydroxylase (TH) and tryp-
tophan hydroxylase (TRH), but both motifs were
changed at single residues in both cases (fig. 1). Exam-
ination of the crystal structure of the N-terminal domain
of dimeric rat PAH (Kobe et al. 1999) revealed that the
GAL and IESRP motifs are in close proximity to each
other on one side of the domain near the surface involved
in dimerization (fig. 2).
Many N-Terminal PAH Mutations Affect Residues
Conserved in PDH
As of October 2000, the PAHMutation Analysis Con-
sortium had identified 256 different PAH missense mu-
tations in patients with hyperphenylalaninemia, includ-
ing 40 (16%) single–amino acid substitutions affecting
a total of 33 residues in the regulatory domain of PAH
(residues 2–120) (fig. 1). Of these N-terminal mutations,
10 (25%) map to the eight residues forming the GAL
and IESRP motifs, suggesting a nonrandom distribution
of mutations ( ). Two or three different dis-Pp .0002
ease-related amino acid substitutions have been recorded
at three of these residues (A47, I65, and R68).
Expression of the PAH Regulatory Domain as Fusion
Protein in E. coli
To examine the molecular consequences of N-terminal
PAH missense mutations, wild-type and mutant (G46S,
A47V, T63P/H64N, I65T, and R68S) forms of the reg-
ulatory domain of PAH (residues 2–120; designated
“PAHRD”) were expressed as fusion proteins withMBP
in E. coli and purified by affinity chromatography. The
preparations were subjected to SDS-PAGE and non-
denaturing PAGE to address the purity, homogeneity,
and oligomeric composition of the fusion proteins. All
purified fusion proteins boiled in SDS migrated as one
band of ∼56 kDa, the expected size of MBP fused to the
regulatory domain of PAH (fig. 3A). When the proteins
were analyzed by native PAGE, some bands and smears
were observed, in addition to the ∼120 kDa dimer, that
probably represent aggregated forms (fig. 3B). Never-
theless, quantitative examination of the gels showed that
the relative amount of aggregates was increased by less
than one-third for all the mutant proteins when com-
pared with the wild-type protein.
N-Terminal PAH Mutations Affect Binding of
Regulatory Phenylalanine
To test whether phenylalanine binds to the wild-type
and mutant forms of the N-terminal PAH domain, pu-
rified MBP-PAHRD fusion proteins were incubated with
different concentrations of radiolabeled phenylalanine,
followed by ultracentrifugation. Figure 4 shows the
binding of phenylalanine to wild-type MBP-PAHRD.
Half maximal binding was obtained at phenylalanine
concentrations of ∼125 mM. The normal plasma phe-
nylalanine level under physiological conditions is 60–
120 mM, and the therapeutic range in children with PAH
deficiency is 120–400 mM. In subsequent experiments,
phenylalanine binding of the five mutant forms of MBP-
PAHRD was examined at substrate concentrations of
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Figure 1 Amino acid–sequence alignment of the N-terminal region of aromatic amino acid hydroxylases and the C-terminal region of
bacterial prephenate dehydratases, using the program PILEUP (Genetics Computer Group). Labeled with their accession names in the SWISS-
PROT database are phenylalanine hydroxylase of Homo sapiens (underlined, PH4H_HUMAN), Mus musculus (PH4H_MOUSE), Rattus
norvegicus (PH4H_RAT), Caenorhabditis elegans (PH4H_CAEEL), and Drosophila melanogaster (PH4H_DROME); prephenate dehydratase
of Corynebacterium glutamicum (PHEA_CORGL), Amycolatopsis methanolica (PHEA_AMYME), Escherichia coli (PHEA_ECOLI), Erwinia
herbicola (PHEA_ERWHE), Haemophilus influenzae (PHEA_HAEIN), Lactococcus lactis (PHEA_LACLA), Bacillus subtilis (PHEA_BACSU),
Pseudomonas stutzeri (PHEA_PSEST), and Methanococcus jannasch (PHEA_METJA); tyrosine hydroxylase of Homo sapiens (TY3H_HUMAN)
and tryptophan hydroxylase of Homo sapiens (TR5H_HUMAN). Naturally occurring PAH missense mutations recorded in PAHdb are indicated
by circles (open, one known mutation; partially filled, two known mutations; filled, three known mutations). Mutations analyzed in the present
study (G46S, A47V, T63P/H64N, I65T, and R68S) are indicated by the substituting amino acid. Residues conserved in 100%, 70%–99%, or
40%–69% of the aligned PAH and PDH sequences are shaded red, yellow, or grey, respectively.
100 mM and 400 mM. As shown in table 1, reduced
phenylalanine binding was observed for all mutant pro-
teins. For three of the mutations, G46S, A47V, and
R68S, phenylalanine binding was not completely abol-
ished, and binding saturation increased significantlywith
increasing phenylalanine concentrations. We noted with
interest that these mutations are all associated with mild
forms of PAH deficiency (Kayaalp et al. 1997; Guldberg
et al. 1998). Although the binding studies presented here
should be considered mainly qualitative, they suggest
that some N-terminal PAH mutations interfere with
binding of phenylalanine to this domain.
Discussion
We provide direct and indirect evidence for a novel
mechanism by which a subset of PAH mutations may
cause enzyme dysfunction and lead to disease. Using
protein database searches, we delineated a region in the
N-terminal regulatory domain of PAHwith overall weak
homology to the regulatory domain of PDH, the rate-
limiting enzyme in bacterial phenylalanine biosynthesis.
Two motifs, GAL (residues 46–48 in human PAH) and
(I/L)ESRP (residues 65–69 in human PAH) were con-
served in PAH from all examined eukaryotic organisms,
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Figure 2 Crystal structure modelling of dimeric rat PAH (PDB
file: Kobe et al. 1999). The conserved motifs, GAL (residues 46–48)
and IESRP (residues 65–69) are located in close proximity to each
other in the regulatory domain near the dimerization interface. The
figure was generated with the SWISS-MODEL and the SWISS-
PdbViewer (Guex and Peitsch 1997).
Figure 3 Analysis of purified MBP-PAHRD fusion proteins
(wild-type and mutant forms) by SDS-PAGE (A) and nondenaturing
PAGE (B). The positions of molecular-weight markers are indicated
(in kDa). Under denaturing conditions, all proteins migrate predom-
inantly as a 56-kDa band. Under nondenaturing conditions, the wild-
type protein migrates almost entirely as a dimer, whereas some of the
mutant proteins represent several molecular forms.
including the distantly related Caenorhabditis elegans,
and, with very few exceptions, in PDH from a wide
range of microorganisms (Pohnert et al. 1999). In ad-
dition, four residues (60–63) in the region preceding the
IESRP motif showed a high degree of evolutionary con-
servation. A large proportion of PAH mutations iden-
tified in patients with hyperphenylalaninemia cluster
within or around the GAL and IESRP motifs, further
suggesting that these residues are important for the func-
tion of PAH.
The binding of phenylalanine to the regulatory do-
main of PDH has been characterized in detail in E. coli
(Nelms et al. 1992; Zhang et al. 1998; Pohnert et al.
1999). In this organism, the first two enzymes involved
in the conversion of phenylalanine from chorismate,
chorismate mutase, and PDH, are combined in the bi-
functional P-protein encoded by the pheA gene. Phe-
nylalanine biosynthesis is controlled by phenylalanine-
mediated feedback inhibition of the chorismate mutase
and PDH activities. The PDH regulatory domain of the
P-protein was purified as a dimer and was shown to
possess a phenylalanine-binding capacity comparable
with those of other amino acid–binding proteins (Poh-
nert et al. 1999). The GAL and LESRP regions repre-
sent, respectively, the hydrophobic and hydrophilic
maxima in this domain, and R331 (homologous to R68
in human PAH) has been suggested to directly interact
with the carboxylic acid group in phenylalanine (Poh-
nert et al. 1999). Site-directed mutagenesis experiments
showed that changes in the GAL and LESRP regions
affected phenylalanine binding, subsequent conforma-
tion changes, and feedback inhibition, to different ex-
tents (Pohnert et al. 1999). Furthermore, nitrous-
acid–induced pheA mutations causing almost total
resistance of the P-protein to feedback inhibition
mapped to residues 304–310, corresponding to residues
41–47 in human PAH (Nelms et al. 1992).
Taken together, the data from these studies of the E.
coli P-protein strongly corroborate the data from our
studies of human PAH. First, the regulatory domain of
PAH (residues 2–120), like the regulatory domain of
PDH, formed a dimer when expressed as a fusion pro-
tein in E. coli. Second, this fusion protein was able to
specifically bind phenylalanine at physiological concen-
trations. Third, naturally occurring PAH mutations
completely abolished or significantly reduced the ca-
pacity of this domain to bind phenylalanine. We noted
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Figure 4 Phenylalanine binding to wild-type MBP-PAHRD fu-
sion protein given in percent of saturation (mean of triplicates 
standard deviation). The binding was calculated under the assumption
of one phenylalanine-binding site per protein monomer.
Table 1
Binding Saturation of Wild-Type and Mutant Forms of MBP-PAHRD
MBP-PAHRD ALLELE
MEAN  SD BINDING SATURATION (%)
AT PHENYLALANINE CONCENTRATION
100 mM 400 mM
Wild-type 39  9 116  24
G46S 6.0  1.1 19  6
A47V 7.2  2.6 38  2
T63P/H64N 0a 0a
I65T 0a 0a
R68S 13  5 51  9
NOTE.—The values were calculated under the assumption of one
phenylalanine-binding site per monomer (mean of triplicates stan-
dard deviation).
a Not distinguishable from background.
with interest that among the PDH mutants examined
by Pohnert et al. (1999), the A310V and L311S variants
(homologous to the naturally occurring A47V and L48S
variants of human PAH) significantly reduced phenyl-
alanine binding. Furthermore, a single–amino acid sub-
stitution of G309 (homologous to G46 in human PAH)
was found among the induced pheA mutations that
cause resistance of the P-protein to phenylalanine-me-
diated feedback inhibition (Nelms et al. 1992).
Recently, Eiken et al. (1996) andWaters et al. (1998a,
1999, 2000) provided evidence that N-terminal PAH
mutations affect the stability of PAH and increase the
protein degradation rate in vitro. Therefore, it could be
argued that the observed reduction in the phenylalanine-
binding capacity of mutant PAH regulatory sites can be
ascribed to protein misfolding. Analysis of the oligo-
meric composition of the regulatory domain of PAH
expressed as a fusion protein showed some higher–
molecular-weight forms for some mutations, presuma-
bly representing aggregated proteins, and we cannot ex-
clude the possibility that this tendency towards aggre-
gation may be even stronger in the multidomain
holoenzyme. However, for all mutant fusion proteins,
the ratio between aggregates and dimer was less than
one-third higher than that measured for the wild-type
protein, and there was no correlation between the
amount of dimer in the protein preparation and the
ability to bind phenylalanine. Therefore, it seems rea-
sonable to suggest that aberrant phenylalanine binding,
leading to lack of subsequent activation, and improper
folding, leading to protein instability, are mechanisms
acting in concert for some mutant PAH proteins. In
support of this notion, Eiken et al. (1996) showed lack
of positive cooperativity of phenylalanine binding for
PAH carrying the G46S mutation, suggesting loss of
phenylalanine-dependent activation.
Although there is now substantial evidence that the
PAH mutation genotype is the major determinant of the
metabolic phenotype in PAH deficiency, a series of re-
cent reports has provided documentation of cases where
patients with identical PAH mutation genotypes exhibit
different degrees of PAH deficiency (Scriver and Waters
1999). Notably, the F39L, L48S, I65T, and R68S mu-
tations, all of which are located in the N-terminal do-
main of PAH, have been associated with a wide range
of metabolic phenotypes, from classical PKU to mild
PKU (Kayaalp et al. 1997; Guldberg et al. 1998). The
existence of a mechanism by which some PAH muta-
tions produce desensitization of the enzyme to the ac-
tivating effect of phenylalanine, as suggested by the pre-
sent data, may explain some of these discordant
genotype-phenotype associations. One attractive hy-
pothesis would be that the activity of these mutant en-
zymes are subject to regulation by substrate concentra-
tions and, accordingly, depend on the concentration of
phenylalanine in the liver. We are presently investigating
the degree to which phenylalanine tolerance depends on
target plasma phenylalanine levels during treatment in
patients with mutations in the regulatory domain of
PAH.
PAH belongs to a family of aromatic amino acid hy-
droxylases, including TH and TRH, which share many
structural and physical properties and catalyze key steps
in the synthesis of neurotransmitters. On the basis of
the sequences of the PAH, TH, and TRH genes and
recent X-ray crystallographic studies of PAH and TH
(Erlandsen et al. 1997; Goodwill et al. 1997; Fusetti et
al. 1998; Kobe et al. 1999), it has been established that
the three hydroxylases share significant homology in the
C-terminal two-thirds of the proteins—that is, the re-
gion comprising the catalytic core. The N-terminal do-
main shares less homology among the vertebrate and
invertebrate hydroxylases and is entirely absent in bac-
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terial PAH, which is not subject to allosteric regulation
by phenylalanine. Neckameyer and White (1992)
showed that PAH and TRH activities are encoded by a
single gene in Drosophila melanogaster and suggested
the existence of an ancestral gene encoding a hydrox-
ylase that most strongly resembles PAH in structure and
function. An attractive model is that this gene, after an
initial duplication event, diverged to form TH and TRH
during the evolution of the vertebrate nervous system.
On the basis of the data presented here, we propose
that the common progenitor for the three vertebrate
aromatic amino acid hydroxylases was formed by jux-
taposition of bacterial PAH with the regulatory domain
of PDH, and that evolutionary changes in this domain
have conferred at least some of the regulatory properties
of the different hydroxylases. On the basis of the crystal
structures of rat and human PAH, Kobe et al. (1999),
Erlandsen and Stevens (1999), and Jennings et al. (2000)
suggested that naturally occurring PAH missense mu-
tations may be assigned to three main categories ac-
cording to the residues affected: (i) residues in the active
site, (ii) residues in key structural domains anywhere in
the protein, and (iii) residues in the domain interfaces.
The different lines of evidence presented here would
suggest a fourth category: mutations affecting residues
directly involved in the binding of phenylalanine to the
regulatory domain of PAH. Although such categoriza-
tion may be useful from a functional point of view, there
is now strong in vitro evidence that most PAH muta-
tions exert their pathogenic effect through the concerted
action of different mechanisms. A major challenge for
future research is to determine the predominant mech-
anisms of individual PAH mutations in vivo.
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